72031
document
Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder . AIM A gluten- and casein-free diet is often given to children with autism spectrum disorder ( ASD ) . We aimed to determine the effect of gluten and casein supplementation on maladaptive behaviour , gastrointestinal symptom severity and intestinal fatty acids binding protein ( I-FABP ) excretion in children with ASD . METHODS A randomised , controlled , double-blind trial was performed on 74 children with ASD with severe maladaptive behaviour and increased urinary I-FABP . Subjects were randomised to receive gluten-casein or a placebo for seven days . We evaluated maladaptive behaviour before and after supplementation , using I-FABP excretion , the approach withdrawal problem composite subtest of the Pervasive Developmental Disorder Behavior Inventory and the Gastrointestinal Symptom Severity Index . RESULTS The mean approach withdrawal problem composite score was significantly higher before supplementation than after , both in the placebo and in the gluten-casein group . However , the mean difference was not significant and may have been caused by additional therapy . There was no significant difference in gastrointestinal symptoms and urinary I-FABP excretion . CONCLUSION Administrating gluten-casein to children with ASD for one week did not increase maladaptive behaviour , gastrointestinal symptom severity or urinary I-FABP excretion . The effect of prolonged administration or other mechanisms of enterocyte damage in ASD should be explored .
72032
Intervention_Pharmacological
Gluten and casein supplementation
72033
Intervention_Pharmacological
gluten- and casein-free diet
72034
Intervention_Control
gluten-casein
72035
Intervention_Control
placebo
72036
Intervention_Pharmacological
gluten-casein
72037
Intervention_Pharmacological
gluten-casein
72038
Participant_Age
children
72039
Participant_Condition
autism spectrum disorder
72040
Participant_Sample-size
74
72041
Participant_Age
children
72042
Participant_Condition
maladaptive behaviour
72043
Participant_Condition
urinary I-FABP
72044
Participant_Condition
Subjects were randomised to receive gluten-casein or a placebo for seven days